EUCTR2017-000852-24-GB进行中（未招募）1 期
A Phase I/II, Open label, Multicentre, Ascending Single Dose, Safety Study of a Novel Adeno-associated Viral Vector (FLT180a) in Patients With Haemophilia B
niversity College London (UCL)0 个研究点目标入组 24 人开始时间: 2017年5月15日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Adults males, = 18 years of age;
- •2. Confirmed diagnosis of HB defined as one of the following: Documented severe FIX deficiency with plasma FIX activity of <1% of normal or moderately severe FIX deficiency with plasma FIX activity level between =1% and =2% and a severe bleeding phenotype defined by one of the following:
- •(a) On prophylaxis for a history of bleeding, or
- •(b) On demand therapy with a history of 4 or more bleeding episodes/year on average over the past 3 years, or
- •(c) Evidence of chronic haemophilic arthropathy (pain, joint destruction, and loss of range of motion).
- •3. Able to give full informed consent and able to comply with all requirements of the trial including 15-year long-term follow-up;
- •4. Willing to practice barrier contraception until at least three consecutive semen samples after vector administration are negative for vector sequences;
- •5. Lack of neutralising anti-AAV-S3 antibodies using an in-vivo transduction inhibition assay within 4 weeks of vector administration.
- •6. At least 150 exposure days to FIX concentrates.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •1. Presence of neutralising anti-human FIX antibodies (inhibitor, determined by the Bethesda inhibitor assay) at the time of enrolment or a previous history of FIX inhibitor;
- •2. Patients at high risk of thromboembolic events (high risk patients would include those with a history of arterial or venous thromboembolism (e.g. deep vein thrombosis, pulmonary embolism, non-haemorrhagic stroke, arterial embolus) and those with acquired thrombophilia including conditions such as atrial fibrilation).
- •3. Use of investigational therapy for haemophilia within 30 days before enrolment;
- •4. Patients with active hepatitis B or C, and HBsAg or HCV RNA viral load positivity, respectively, or currently on antiviral therapy for hepatitis B or C. (Negative viral assays in 2 samples, collected at least 5 months apart, will be required to be considered negative. Both natural clearers and those who have cleared HCV on antiviral therapy are eligible.);
- •5. Serological evidence of HIV-1;
- •6. Evidence of liver dysfunction (persistently elevated alanine aminotransferase, aspartate aminotransferase, bilirubin >1.5 x upper limit of normal).
- •7. Platelet count <50x109/L;
- •8. Uncontrolled glaucoma, diabetes mellitus, or hypertension;
- •9. Malignancy requiring treatment;
- •10. Patients with uncontrolled cardiac failure, unstable angina or myocardial infarction in the past 6 months.
- •11. Poor performance status (World Health Organization score >1);
- •12. Prior treatment with any gene transfer medicinal product;
- •13. Known or suspected intolerance, hypersensitivity or contrainidication to the investigational product and non-investigational medicinal products or their excipients;
- •14.Planned major elective surgery prior to the end of trial.
- •15. Current or relevant history of a physical or psychiatric illness or any medical condition that in the opinion of the investigator could affect the patients safety or interfere with the study assessments.
- •16. CMV IgG positive patients who are CMV PCR positive at screening.
研究者
相似试验
进行中（未招募）
1 期
A Factor IX Gene Therapy Study (FIX-GT)Haemophilia BMedDRA version: 20.0Level: LLTClassification code 10018939Term: Haemophilia B (Factor IX)System Organ Class: 100000004850EUCTR2017-000852-24-ITIVERSITY COLLEGE LONDO24
进行中（未招募）
1 期
A Phase I/II, Multicenter, Open-Label, PK, Safety and Efficacy Study to Evaluate Raltegravir in HIV-1 Infected YouthEUCTR2009-015884-15-Outside-EU/EEAThe National Institute of Allergy and Infectious Diseases (NIAID) and The Eunice Kennedy Shriver NICHD138
已完成
1 期
A Phase I/II study of ASTX660 in patients with relapsed or refractory T-cell lymphomaJPRN-jRCT2080225162Otsuka Pharmaceutical Co., LTD.61
已完成
2 期
A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, versus Enzalutamide alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abirateronecastration resistant prostate cancer10038593NL-OMON43930Boehringer Ingelheim BV6
进行中（未招募）
1 期
BI 836845 plus enzalutamide in castrate resistant prostate cancer (CRPC)Patients with metastatic castrate resistent prostate cancer (CRPC)EUCTR2013-004011-41-NLBoehringer Ingelheim bv120